PortalPublikationenRadical prostatectomy for localized prostate cancer: 20-year...

Radical prostatectomy for localized prostate cancer: 20-year oncological outcomes from a German high-volume center

Standard

Radical prostatectomy for localized prostate cancer: 20-year oncological outcomes from a German high-volume center. / Würnschimmel, Christoph; Wenzel, Mike; Wang, Nuowei; Tian, Zhe; Karakiewicz, Pierre I; Graefen, Markus; Huland, Hartwig; Tilki, Derya.

in: UROL ONCOL-SEMIN ORI, Jahrgang 39, Nr. 12, 12.2021, S. 830.e17-830.e26.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Würnschimmel, C, Wenzel, M, Wang, N, Tian, Z, Karakiewicz, PI, Graefen, M, Huland, H & Tilki, D 2021, 'Radical prostatectomy for localized prostate cancer: 20-year oncological outcomes from a German high-volume center', UROL ONCOL-SEMIN ORI, Jg. 39, Nr. 12, S. 830.e17-830.e26. https://doi.org/10.1016/j.urolonc.2021.04.031

APA

Würnschimmel, C., Wenzel, M., Wang, N., Tian, Z., Karakiewicz, P. I., Graefen, M., Huland, H., & Tilki, D. (2021). Radical prostatectomy for localized prostate cancer: 20-year oncological outcomes from a German high-volume center. UROL ONCOL-SEMIN ORI, 39(12), 830.e17-830.e26. https://doi.org/10.1016/j.urolonc.2021.04.031

Vancouver

Würnschimmel C, Wenzel M, Wang N, Tian Z, Karakiewicz PI, Graefen M et al. Radical prostatectomy for localized prostate cancer: 20-year oncological outcomes from a German high-volume center. UROL ONCOL-SEMIN ORI. 2021 Dez;39(12):830.e17-830.e26. https://doi.org/10.1016/j.urolonc.2021.04.031

Bibtex

@article{f2b7203797d0464da56066bce993b301,
title = "Radical prostatectomy for localized prostate cancer: 20-year oncological outcomes from a German high-volume center",
abstract = "INTRODUCTION: Long-term outcomes of prostate cancer (CaP) patients treated with radical prostatectomy (RP) from European cohorts are under-reported. We report on 22,843 RP patients from the Martini-Klinik Prostate Cancer Centre treated between 1992 and 2017.PATIENTS AND METHODS: Biochemical recurrence (BCR) free survival, metastasis free survival (MFS), and cancer specific survival (CSS) were stratified according to National Comprehensive Cancer Network (NCCN) risk categories, pT, and pN stages, RP Gleason Grade Groups (GGG), and surgical margin status (R0/R1). For time to event analyses, uni- and multivariable Cox's proportional hazards models and univariable Kaplan-Meier analyses were applied.RESULTS: Median follow up was 68 months. Most favourable 20-year survival rates were exhibited in NCCN low risk (78.7% BCR-free, 96.8% MFS, 90.1% CSS) and pT2, GGG 1 to 2, R0 patients (83.1% BCR-free, 96.7% MFS, 92.6% CSS). 20-year follow up was not constantly reached in patients with aggressive CaP features. For example, NCCN very high-risk patients exhibited 15-year BCR-free survival of 30.5%, while 20-year MFS and CSS in these individuals was reached (64.1% and 60.8%, respectively). Lowest 10-year BCR-free survival (35.6%) was exhibited in pT3b, GGG 4 to 5, R0. Lowest 10-year MFS (49.5%) was exhibited in pT2, GGG 4 to 5, R1. Lowest 10-year CSS (69.8%) was exhibited in pT3b, GGG 4 to 5, R1 patients. In separate pN1 analyses, lowest 10-year BCR-free survival (14.5%), MFS (56.9%), and CSS (71.9%) were exhibited in patients with 3 or more positive lymph nodes.CONCLUSION: Oncological outcomes after RP can be excellent for individuals with favorable CaP characteristics, also after 20 years of follow up.",
author = "Christoph W{\"u}rnschimmel and Mike Wenzel and Nuowei Wang and Zhe Tian and Karakiewicz, {Pierre I} and Markus Graefen and Hartwig Huland and Derya Tilki",
note = "Copyright {\textcopyright} 2021 Elsevier Inc. All rights reserved.",
year = "2021",
month = dec,
doi = "10.1016/j.urolonc.2021.04.031",
language = "English",
volume = "39",
pages = "830.e17--830.e26",
journal = "UROL ONCOL-SEMIN ORI",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "12",

}

RIS

TY - JOUR

T1 - Radical prostatectomy for localized prostate cancer: 20-year oncological outcomes from a German high-volume center

AU - Würnschimmel, Christoph

AU - Wenzel, Mike

AU - Wang, Nuowei

AU - Tian, Zhe

AU - Karakiewicz, Pierre I

AU - Graefen, Markus

AU - Huland, Hartwig

AU - Tilki, Derya

N1 - Copyright © 2021 Elsevier Inc. All rights reserved.

PY - 2021/12

Y1 - 2021/12

N2 - INTRODUCTION: Long-term outcomes of prostate cancer (CaP) patients treated with radical prostatectomy (RP) from European cohorts are under-reported. We report on 22,843 RP patients from the Martini-Klinik Prostate Cancer Centre treated between 1992 and 2017.PATIENTS AND METHODS: Biochemical recurrence (BCR) free survival, metastasis free survival (MFS), and cancer specific survival (CSS) were stratified according to National Comprehensive Cancer Network (NCCN) risk categories, pT, and pN stages, RP Gleason Grade Groups (GGG), and surgical margin status (R0/R1). For time to event analyses, uni- and multivariable Cox's proportional hazards models and univariable Kaplan-Meier analyses were applied.RESULTS: Median follow up was 68 months. Most favourable 20-year survival rates were exhibited in NCCN low risk (78.7% BCR-free, 96.8% MFS, 90.1% CSS) and pT2, GGG 1 to 2, R0 patients (83.1% BCR-free, 96.7% MFS, 92.6% CSS). 20-year follow up was not constantly reached in patients with aggressive CaP features. For example, NCCN very high-risk patients exhibited 15-year BCR-free survival of 30.5%, while 20-year MFS and CSS in these individuals was reached (64.1% and 60.8%, respectively). Lowest 10-year BCR-free survival (35.6%) was exhibited in pT3b, GGG 4 to 5, R0. Lowest 10-year MFS (49.5%) was exhibited in pT2, GGG 4 to 5, R1. Lowest 10-year CSS (69.8%) was exhibited in pT3b, GGG 4 to 5, R1 patients. In separate pN1 analyses, lowest 10-year BCR-free survival (14.5%), MFS (56.9%), and CSS (71.9%) were exhibited in patients with 3 or more positive lymph nodes.CONCLUSION: Oncological outcomes after RP can be excellent for individuals with favorable CaP characteristics, also after 20 years of follow up.

AB - INTRODUCTION: Long-term outcomes of prostate cancer (CaP) patients treated with radical prostatectomy (RP) from European cohorts are under-reported. We report on 22,843 RP patients from the Martini-Klinik Prostate Cancer Centre treated between 1992 and 2017.PATIENTS AND METHODS: Biochemical recurrence (BCR) free survival, metastasis free survival (MFS), and cancer specific survival (CSS) were stratified according to National Comprehensive Cancer Network (NCCN) risk categories, pT, and pN stages, RP Gleason Grade Groups (GGG), and surgical margin status (R0/R1). For time to event analyses, uni- and multivariable Cox's proportional hazards models and univariable Kaplan-Meier analyses were applied.RESULTS: Median follow up was 68 months. Most favourable 20-year survival rates were exhibited in NCCN low risk (78.7% BCR-free, 96.8% MFS, 90.1% CSS) and pT2, GGG 1 to 2, R0 patients (83.1% BCR-free, 96.7% MFS, 92.6% CSS). 20-year follow up was not constantly reached in patients with aggressive CaP features. For example, NCCN very high-risk patients exhibited 15-year BCR-free survival of 30.5%, while 20-year MFS and CSS in these individuals was reached (64.1% and 60.8%, respectively). Lowest 10-year BCR-free survival (35.6%) was exhibited in pT3b, GGG 4 to 5, R0. Lowest 10-year MFS (49.5%) was exhibited in pT2, GGG 4 to 5, R1. Lowest 10-year CSS (69.8%) was exhibited in pT3b, GGG 4 to 5, R1 patients. In separate pN1 analyses, lowest 10-year BCR-free survival (14.5%), MFS (56.9%), and CSS (71.9%) were exhibited in patients with 3 or more positive lymph nodes.CONCLUSION: Oncological outcomes after RP can be excellent for individuals with favorable CaP characteristics, also after 20 years of follow up.

U2 - 10.1016/j.urolonc.2021.04.031

DO - 10.1016/j.urolonc.2021.04.031

M3 - SCORING: Journal article

C2 - 34092484

VL - 39

SP - 830.e17-830.e26

JO - UROL ONCOL-SEMIN ORI

JF - UROL ONCOL-SEMIN ORI

SN - 1078-1439

IS - 12

ER -